Clairity Breast is the first FDA-authorized AI platform that predicts a woman’s five-year future risk of developing breast cancer, using only her existing screening mammogram.
“For more than 60 years, mammograms have saved lives by detecting early-stage cancers. Now, advancements in AI and computer vision can uncover hidden clues in the mammograms – invisible to the human eye – to help predict future risk. By delivering validated, equitable risk assessments, we can help expand access to life-saving early detection and prevention for women everywhere.”
Dr. Connie Lehman
In a new study published in Radiology, BCRF investigator Dr. Connie Lehman, founder of Clairity Breast and professor of radiology at Harvard Medical School, and colleagues found that AI-detected signals can change over time, producing a dynamic risk score that evolves and offers insight into long-term risk.
AI-powered risk scoring could enable a more personalized approach to breast cancer screening and prevention
Clairity is launching soon at health systems across the USA. Sign up to be notified when it’s available at a health system near you.
